Lauren Len Spiegel, MD
Neurology · Morgan Hill
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 35
- 9 carriers
- Offices
- 3
Offices
3 locations · Bass Medical Group · 292 clinicians in this group
Hospitals listed: 059765 · Good Samaritan Hospital · Hazel Hawkins Memorial Hospital · Santa Clara Valley Medical Center · Stanford Health Care. That is not proof they admit you there this week.
Plans that list them
35 plans · 9 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Spiegel’s office to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
35 of 35 plans
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Silicon (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health smartHMO (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health the ONE (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Anthem Full Dual Advantage Aligned (HMO D-SNP) | Anthem Blue Cross | Listed | Oct 3, 2026 |
| Anthem Medicare Advantage (HMO-POS) | Anthem Blue Cross | Listed | Oct 3, 2026 |
| Anthem Prime (HMO-POS) | Anthem Blue Cross Partnership Plan | Listed | Oct 3, 2026 |
| Astiva Health C-SNP WOW - NorCal (HMO C-SNP) | Astiva Health | Listed | Sep 27, 2026 |
| Astiva Health Premier Plan - NorCal (HMO) | Astiva Health | Listed | Sep 27, 2026 |
| Astiva Health Savings Plan - NorCal (HMO) | Astiva Health | Listed | Sep 27, 2026 |
| Blue Shield Inspire (HMO) | Blue Shield of California | Listed | Aug 26, 2026 |
| Central Health Classic Care Plan III (HMO) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Central Health Dual Access Plan (HMO D-SNP) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Central Health Embrace Care Plan (HMO C-SNP) | Central Health Medicare Plan | Listed, may be out of date | Sep 15, 2025 |
| Central Health Embrace Choice Plan (HMO C-SNP) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Central Health Valor Care Plan (HMO) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Imperial Courage Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Dynamic Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Senior Value (HMO C-SNP) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Kaiser Permanente Dual Complete North P2 (HMO D-SNP) | Kaiser Permanente | Listed | Sep 1, 2026 |
| Kaiser Permanente Dual Complete North P23 (HMO D-SNP) | Kaiser Permanente | Listed | Sep 1, 2026 |
| Kaiser Permanente Sr Adv Basic Santa Clara (HMO) | Kaiser Permanente | Listed | Sep 1, 2026 |
| Kaiser Permanente Sr Adv Enhanced Santa Clara (HMO) | Kaiser Permanente | Listed | Sep 1, 2026 |
| SCAN Balance (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Classic (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN MyChoice (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Strive (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
California Medical Board record
Licence A153605 · Current
Licensed to practise in California · since 2018 · expires 2027-03-31 · Medical College of Georgia at Georgia Regents University.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
4 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Good Samaritan HospitalSan Jose, CAAcute Care Hospital · Proprietary · Has an emergency department · Birthing-friendlyPart of HCA Healthcare, which runs 185 hospitals in 19 statesPatients rate it 2 of 5 · 67% would definitely recommend itOverall rating: 2 of 5 starsBetter than the national rate — Clostridium Difficile (C.Diff): 0.337, Oct 2024 – Sep 2025
- Hazel Hawkins Memorial HospitalHollister, CACritical Access Hospital · Government - Hospital District or Authority · Has an emergency departmentNo overall ratingNo measure marked better or worse than the national rate
- Santa Clara Valley Medical CenterSan Jose, CAAcute Care Hospital · Government - Local · Has an emergency department · Birthing-friendlyPart of Santa Clara Valley Health and Hospital System, which runs 3 hospitalsPatients rate it 3 of 5 · 70% would definitely recommend itOverall rating: 2 of 5 starsWorse than the national rate — SSI - Colon Surgery: 2.572, Oct 2024 – Sep 2025Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.563, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.256, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0.369, Oct 2024 – Sep 2025
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for Good Samaritan Hospital
Behind the star rating — Deaths: 0 better, 8 the same, 0 worse of 8 measures. Safety: 1 better, 6 the same, 1 worse of 8 measures. Readmissions: 0 better, 5 the same, 4 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Clostridium Difficile (C.Diff)Infections | 0.337 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.75 (0 to 1.67) · 1,340 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.84 (0.54 to 1.14) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 143.59 (98.7 to 188.49) · 98 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.7 · 45 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.1 · 100 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 12.7 · 270 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 11.3 · 573 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 15.6 · 820 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.5 · 482 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.3 · 3,711 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.12 (0 to 0.3) · 8,866 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.2 (0.01 to 0.38) · 9,051 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 2.65 (0.74 to 4.56) · 1,929 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.8 (0.21 to 3.39) · 670 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.33 (0.88 to 3.78) · 1,836 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 6.73 (0 to 13.46) · 669 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 7.58 (3.96 to 11.19) · 654 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.59 (0.13 to 3.04) · 496 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.27 (0 to 0.87) · 7,373 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4.1 · 152 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 1.08 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.542 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.484 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.565 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 15.8 · 327 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 24.2 · 703 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 61.1 · 289 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 36.3 · 665 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 25.4 · 856 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 19 · 978 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 6.3 · 144 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 12.3 · 46 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 21.2 · 135 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.8 (10.1 to 18.6) · 129 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1.2 (0.9 to 1.5) · 531 cases | No different | Jan 2024 – Dec 2024 |
What patients said (704 patients answered, 24% of those asked)
| Cleanliness | 3 |
| Nurse communication | 3 |
| Doctor communication | 2 |
| Communication about medicines | 2 |
| Discharge information | 3 |
| Overall hospital rating | 2 |
| Quietness | 1 |
| Recommend hospital | 3 |
| Room was "always" clean | 66% |
| Nurses "always" communicated well | 75% |
| Doctors "always" communicated well | 71% |
| Staff "always" explained | 54% |
| Yes, staff "did" give patients this information | 83% |
| Yes, staff "did" give patients information about help after discharge | 81% |
| Doctors "always" explained things so they could understand | 66% |
| Doctors "always" listened carefully | 69% |
| Doctors "always" treated them with courtesy and respect | 78% |
| Patients who gave a rating of "9" or "10" (high) | 63% |
| Staff "always" explained new medications | 68% |
| Nurses "always" explained things so they could understand | 69% |
| Nurses "always" listened carefully | 73% |
| Nurses "always" treated them with courtesy and respect | 82% |
| "Always" quiet at night | 38% |
| "YES", patients would definitely recommend the hospital | 67% |
| Staff "always" explained possible side effects | 40% |
| Yes, staff "did" give patients information about possible symptoms | 86% |
See every measure and the patient survey for Hazel Hawkins Memorial Hospital
Behind the star rating — Readmissions: 0 better, 2 the same, 0 worse of 2 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.8 (9.6 to 17.1) · 409 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.7 to 1.4) · 43 cases | No different | Jan 2024 – Dec 2024 |
See every measure and the patient survey for Santa Clara Valley Medical Center
Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 2 better, 5 the same, 1 worse of 8 measures. Readmissions: 0 better, 10 the same, 1 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| SSI - Colon SurgeryInfections | 2.572 | Worse | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.563 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.256 | Better | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.369 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.25 (0.3 to 2.2) · 1,535 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.07 (0.76 to 1.38) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 214.59 (167.38 to 261.8) · 108 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.8 · 41 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6 · 141 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10.2 · 124 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 8.3 · 501 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 14.9 · 653 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.1 · 348 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3 · 4,502 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.24 (0.04 to 0.43) · 9,014 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.34 (0.15 to 0.52) · 9,216 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 4.54 (2.51 to 6.58) · 1,421 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.54 (0 to 3.2) · 288 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.11 (0.66 to 3.56) · 1,446 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 11.61 (4.09 to 19.14) · 294 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 7.29 (3.39 to 11.2) · 299 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.9 (0.45 to 3.36) · 333 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.23 (0 to 0.78) · 7,538 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 5.4 · 94 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.735 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 2.573 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.6 · 185 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 22.1 · 951 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 56.3 · 128 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 6.4 · 644 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 1.3 · 699 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.3 · 921 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.7 (3.9 to 8.1) · 226 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 12.6 (9.4 to 16.5) · 226 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.4 · 94 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 11.4 · 54 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.3 · 242 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.2 (9.9 to 17.4) · 702 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.7 to 1.4) · 195 cases | No different | Jan 2024 – Dec 2024 |
What patients said (4,032 patients answered, 29% of those asked)
| Cleanliness | 3 |
| Nurse communication | 3 |
| Doctor communication | 3 |
| Communication about medicines | 3 |
| Discharge information | 2 |
| Overall hospital rating | 3 |
| Quietness | 2 |
| Recommend hospital | 4 |
| Room was "always" clean | 70% |
| Nurses "always" communicated well | 73% |
| Doctors "always" communicated well | 76% |
| Staff "always" explained | 57% |
| Yes, staff "did" give patients this information | 82% |
| Yes, staff "did" give patients information about help after discharge | 82% |
| Doctors "always" explained things so they could understand | 71% |
| Doctors "always" listened carefully | 74% |
| Doctors "always" treated them with courtesy and respect | 82% |
| Patients who gave a rating of "9" or "10" (high) | 67% |
| Staff "always" explained new medications | 71% |
| Nurses "always" explained things so they could understand | 71% |
| Nurses "always" listened carefully | 69% |
| Nurses "always" treated them with courtesy and respect | 80% |
| "Always" quiet at night | 43% |
| "YES", patients would definitely recommend the hospital | 70% |
| Staff "always" explained possible side effects | 44% |
| Yes, staff "did" give patients information about possible symptoms | 83% |
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$352,414
Medicare paid this office $352,414 for 747 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Botox | 44 | $149,569 | None |
| Return visit (30+ min) | 402 | $62,327 | $118 |
| Short return visit (20+ min) | 365 | $38,497 | $83 |
| New patient visit (45+ min) | 159 | $24,980 | $157 |
| Exam of neurobehavioral status, first hour | 199 | $16,139 | $80 |
See all 13 services
| Botox | 44 | $149,569 | None |
| Return visit (30+ min) | 402 | $62,327 | $118 |
| Short return visit (20+ min) | 365 | $38,497 | $83 |
| New patient visit (45+ min) | 159 | $24,980 | $157 |
| Exam of neurobehavioral status, first hour | 199 | $16,139 | $80 |
| Injection of chemical for paralysis of nerve muscles on side of neck excluding voice box | 29 | $12,733 | $177 |
| Muscle electrical test | 38 | $8,371 | $87 |
| Face injection for nerve paralysis | 14 | $7,304 | $203 |
| Injection of chemical for paralysis of nerve muscles on arm or leg, 1-4 muscles, first extremity | 23 | $5,557 | $101 |
| Injection of chemical for paralysis of nerve muscles on arm or leg, 1-4 muscles, each additional extremity | 22 | $4,723 | $93 |
| Testing of autonomic (sympathetic) nervous system function | 32 | $4,216 | $132 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 176 | $3,532 | $15 |
| New patient visit (30+ min) | 25 | $2,594 | $104 |
Who their Medicare patients are
747 Original Medicare patients in 2024. Average age 77 · Under 65 3% · 85 and older 17% · Women 57% · Also on Medicaid 4% · Health risk score 1.36. At or below the middle of the specialty; the typical neurology clinician is at 1.61.
Conditions among them: High blood pressure 75% · Coronary heart disease 32% · Diabetes 30% · Depression 27% · Dementia 27% · Stroke 24% · Atrial fibrillation 20% · Chronic kidney disease 18% · Cancer 17% · Heart failure 15% · COPD 13%.
The office billed $1,216,642, Medicare allowed $461,277 and paid $352,414; for 34,102 services of 32 kinds; $153,956 of it was for drugs given in the office and $198,458 for care.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 747 | 34,102 | 77 | 1.36 | $1,216,642 | $352,414 |
| 2023 | 662 | 30,684 | 77 | 1.24 | $1,199,474 | $343,661 |
| 2022 | 471 | 17,460 | 77 | 1.32 | $879,516 | $242,601 |
| 2021 | 263 | 8,086 | 76 | 1.28 | $532,299 | $149,733 |
| 2020 | 118 | 366 | 74 | 1.22 | $77,730 | $17,402 |
| 2019 | 154 | 322 | 71 | 1.44 | $191,297 | $23,789 |
| 2018 | 98 | 186 | 70 | 1.26 | $126,350 | $16,900 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 13 services
| Botox | 47 | $142,250 | None |
| Return visit (30+ min) | 385 | $58,369 | $117 |
| Short return visit (20+ min) | 296 | $42,808 | $83 |
| New patient visit (45+ min) | 248 | $37,399 | $151 |
| Exam of neurobehavioral status, first hour | 177 | $15,531 | $85 |
| Injection of chemical for paralysis of nerve muscles on side of neck excluding voice box | 27 | $9,621 | $160 |
| Muscle electrical test | 41 | $7,276 | $85 |
| Testing of autonomic (sympathetic) nervous system function | 43 | $5,528 | $129 |
| Face injection for nerve paralysis | 13 | $5,174 | $199 |
| Injection of chemical for paralysis of nerve muscles on arm or leg, 1-4 muscles, first extremity | 26 | $5,097 | $96 |
| Injection of chemical for paralysis of nerve muscles on arm or leg, 1-4 muscles, each additional extremity | 25 | $4,428 | $89 |
| New patient visit (30+ min) | 28 | $2,823 | $101 |
| Test or measurement for functional capacity, each 15 minutes | 23 | $792 | $34 |
2022: 10 services
| Return visit (30+ min) | 346 | $77,971 | $116 |
| Botox | 32 | $76,858 | None |
| New patient visit (45+ min) | 242 | $35,896 | $148 |
| Exam of neurobehavioral status, first hour | 141 | $12,390 | $86 |
| Short return visit (20+ min) | 120 | $11,493 | $80 |
| Injection of chemical for paralysis of nerve muscles on side of neck excluding voice box | 22 | $7,374 | $168 |
| Muscle electrical test | 28 | $4,799 | $86 |
| Injection of chemical for paralysis of nerve muscles on arm or leg, 1-4 muscles, each additional extremity | 16 | $2,576 | $89 |
| Injection of chemical for paralysis of nerve muscles on arm or leg, 1-4 muscles, first extremity | 20 | $2,486 | $83 |
| Test or measurement for functional capacity, each 15 minutes | 15 | $465 | $31 |
2021: 8 services
| Return visit (30+ min) | 212 | $74,194 | $119 |
| Botox | 24 | $34,356 | None |
| New patient visit (45+ min) | 78 | $12,153 | $156 |
| Exam of neurobehavioral status, first hour | 82 | $8,098 | $90 |
| Short return visit (20+ min) | 42 | $3,779 | $86 |
| Long return visit (40+ min) | 18 | $3,200 | $152 |
| New patient visit (60+ min) | 12 | $2,216 | $185 |
| Muscle electrical test | 12 | $1,993 | $91 |
2020: 2 services
| Return visit (30+ min) | 72 | $8,305 | $104 |
| Long return visit (40+ min) | 45 | $5,204 | $113 |
2019: 8 services
| Long return visit (40+ min) | 72 | $7,002 | $88 |
| Extended office or other outpatient service, first hour | 30 | $3,355 | $108 |
| Injection of chemical for paralysis of nerve muscles on side of neck excluding voice box | 24 | $2,981 | $99 |
| New patient visit (60+ min) | 16 | $2,377 | $149 |
| Return visit (30+ min) | 17 | $784 | $46 |
| Muscle electrical test | 34 | $754 | $18 |
| Electronic analysis of implanted brain, spinal cord, or peripheral neurostimulator generator with brain stimulator programming, first 15 minutes with qualified health professional | 14 | $516 | $37 |
| Electronic analysis of implanted brain, spinal cord, or peripheral neurostimulator generator | 21 | $332 | $14 |
2018: 5 services
| Long return visit (40+ min) | 46 | $4,546 | $97 |
| Electronic analysis and programming of implanted complex deep brain neurostimulator generator system, first hour | 13 | $2,076 | $160 |
| Injection of chemical for paralysis of nerve muscles on side of neck excluding voice box | 14 | $1,905 | $136 |
| New patient visit (60+ min) | 12 | $1,644 | $137 |
| Muscle electrical test | 21 | $400 | $18 |
Medicaid work
$28,761 in 2023
Medicaid paid $28,761 for 316 billed services this clinician did in 2023, up to 55 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Clinic visit/encounter, all-inclusive | 218 | $28,761 |
| New patient visit (45+ min) | 30 | $0 |
| Short return visit (20+ min) | 13 | $0 |
| Return visit (30+ min) | 43 | $0 |
| Telephone evaluation and management service by a physician or other qualified health care professional who may report evaluation and management services provided to an established patient, parent, or guardian not originating from a related E/M service provided within the previous 7 days nor leading to an E/M service or procedure within the next 24 hours or soonest available appointment; 21-30 minutes of medical discussion | 12 | $0 |
| 2023 | 316 | 5 | 55 | $28,761 |
Drugs they prescribed that Part D paid
$2,088,189
Pharmacies billed $2,088,189 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 4,221) in 2024. At or below the middle of the specialty; the typical neurology clinician is at 0%.
3,920 generic and fewer than 11 brand-name prescriptions · $2,088,189 in drug cost · 214 antipsychotic prescriptions to people over 65.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Gamunex-C | Immune globulin | 32 | $239,341 | $7,479 |
| Ingrezza | None | 18 | $197,957 | $10,998 |
| Nuplazid | Parkinson's psychosis | 24 | $118,729 | $4,947 |
| Rytary | Parkinson's | 27 | $70,068 | $2,595 |
| Gammagard Liquid | Immune globulin | 13 | $64,288 | $4,945 |
See all 56 drugs
| Gamunex-C | Immune globulin | 32 | $239,341 | $7,479 |
| Ingrezza | None | 18 | $197,957 | $10,998 |
| Nuplazid | Parkinson's psychosis | 24 | $118,729 | $4,947 |
| Rytary | Parkinson's | 27 | $70,068 | $2,595 |
| Gammagard Liquid | Immune globulin | 13 | $64,288 | $4,945 |
| Neupro | None | 35 | $60,800 | $1,737 |
| Copaxone | None | 11 | $60,359 | $5,487 |
| Nuedexta | None | 24 | $56,999 | $2,375 |
| Carbidopa-Levodopa Er | None | 274 | $27,474 | $100 |
| Rivastigmine | None | 72 | $22,503 | $313 |
| Glatiramer Acetate | None | 13 | $20,281 | $1,560 |
| Myrbetriq | None | 27 | $16,305 | $604 |
| Carbidopa-Levodopa | None | 227 | $12,179 | $54 |
| Donepezil | None | 694 | $11,696 | $17 |
| Memantine | None | 295 | $11,551 | $39 |
| Gabapentin | None | 356 | $11,038 | $31 |
| Duloxetine | None | 130 | $8,453 | $65 |
| Propranolol Hcl Er | None | 85 | $7,510 | $88 |
| Quetiapine | None | 160 | $7,293 | $46 |
| Lacosamide | None | 20 | $5,213 | $261 |
| Mirtazapine | None | 107 | $5,165 | $48 |
| Pregabalin | None | 80 | $4,043 | $51 |
| Levetiracetam | None | 79 | $4,026 | $51 |
| Memantine Hcl Er | None | 18 | $3,678 | $204 |
| Aripiprazole | None | 13 | $3,625 | $279 |
| Rasagiline Mesylate | None | 22 | $3,543 | $161 |
| Midodrine | None | 16 | $3,530 | $221 |
| Pyridostigmine | None | 36 | $3,167 | $88 |
| Propranolol | None | 62 | $2,800 | $45 |
| Escitalopram | None | 137 | $2,525 | $18 |
| Oxcarbazepine | None | 23 | $2,491 | $108 |
| Primidone | None | 39 | $2,117 | $54 |
| Rivastigmine | None | 25 | $2,058 | $82 |
| Zonisamide | None | 44 | $1,629 | $37 |
| Trazodone | None | 127 | $1,578 | $12 |
| Baclofen | None | 26 | $1,553 | $60 |
| Clopidogrel | None | 68 | $1,499 | $22 |
| Lamotrigine | None | 48 | $1,350 | $28 |
| Pramipexole Dihydrochloride | None | 43 | $1,215 | $28 |
| Methocarbamol | None | 37 | $1,187 | $32 |
| Cyclobenzaprine | None | 36 | $1,099 | $31 |
| Amantadine | None | 17 | $824 | $48 |
| Tizanidine | None | 31 | $811 | $26 |
| Venlafaxine Hcl Er | None | 40 | $755 | $19 |
| Levetiracetam Er | None | 15 | $727 | $48 |
| Nortriptyline | None | 33 | $646 | $20 |
| Bupropion Xl | None | 28 | $595 | $21 |
| Risperidone | None | 16 | $537 | $34 |
| Ropinirole | None | 19 | $515 | $27 |
| Ondansetron | None | 23 | $397 | $17 |
| Clonazepam | None | 32 | $375 | $12 |
| Sertraline | None | 22 | $285 | $13 |
| Atorvastatin | None | 26 | $262 | $10 |
| Meloxicam | None | 19 | $110 | $6 |
| Diazepam | None | 24 | $63 | $3 |
| Sumatriptan | None | 18 | $30 | $2 |
Year by year
| 2024 | 4,221 | 791 | 0% (0) | None | $2,088,189 |
| 2023 | 3,303 | 659 | 0% (0) | 8% | $1,053,700 |
| 2022 | 1,993 | 435 | None | 9% | $607,840 |
| 2021 | 1,279 | 240 | None | 11% | $383,129 |
| 2020 | 339 | 126 | 0% (0) | 12% | $86,548 |
| 2019 | 641 | 119 | 0% (0) | 10% | $206,640 |
| 2018 | 179 | 55 | 0% (0) | 8% | $31,059 |
| 2017 | 16 | None | 0% (0) | None | $898 |
| 2016 | 46 | 14 | 0% (0) | None | $3,812 |
| 2015 | 22 | None | 0% (0) | 50% | $2,026 |
| 2014 | 23 | None | 0% (0) | None | $765 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 50 drugs
| Nuplazid | Parkinson's psychosis | 45 | $215,776 | $4,795 |
| Ingrezza | None | 19 | $156,971 | $8,262 |
| Rytary | Parkinson's | 34 | $83,646 | $2,460 |
| Copaxone | None | 11 | $70,281 | $6,389 |
| Neupro | None | 28 | $60,032 | $2,144 |
| Carbidopa-Levodopa Er | None | 251 | $42,718 | $170 |
| Rivastigmine | None | 82 | $32,334 | $394 |
| Carbidopa-Levodopa | None | 275 | $24,327 | $88 |
| Nuedexta | None | 12 | $23,448 | $1,954 |
| Myrbetriq | None | 24 | $18,598 | $775 |
| Memantine | None | 211 | $17,579 | $83 |
| Carbidopa | None | 14 | $10,977 | $784 |
| Gabapentin | None | 271 | $10,333 | $38 |
| Rasagiline Mesylate | None | 27 | $9,907 | $367 |
| Propranolol Hcl Er | None | 86 | $9,175 | $107 |
| Donepezil | None | 492 | $8,532 | $17 |
| Quetiapine | None | 130 | $7,779 | $60 |
| Pregabalin | None | 48 | $4,625 | $96 |
| Midodrine | None | 23 | $4,568 | $199 |
| Mirtazapine | None | 81 | $4,330 | $53 |
| Duloxetine | None | 85 | $3,916 | $46 |
| Rivastigmine | None | 28 | $3,827 | $137 |
| Zonisamide | None | 51 | $3,151 | $62 |
| Propranolol | None | 39 | $3,116 | $80 |
| Baclofen | None | 23 | $2,715 | $118 |
| Pyridostigmine | None | 28 | $2,680 | $96 |
| Galantamine Er | None | 14 | $2,666 | $190 |
| Levetiracetam | None | 29 | $1,724 | $59 |
| Escitalopram | None | 84 | $1,449 | $17 |
| Bupropion Xl | None | 30 | $1,409 | $47 |
| Clonazepam | None | 53 | $1,386 | $26 |
| Trazodone | None | 74 | $1,330 | $18 |
| Primidone | None | 18 | $1,168 | $65 |
| Amantadine | None | 11 | $1,051 | $96 |
| Lamotrigine | None | 11 | $773 | $70 |
| Atorvastatin | None | 43 | $769 | $18 |
| Tizanidine | None | 24 | $644 | $27 |
| Cyclobenzaprine | None | 27 | $607 | $22 |
| Nortriptyline | None | 25 | $591 | $24 |
| Divalproex | None | 13 | $570 | $44 |
| Sertraline | None | 26 | $569 | $22 |
| Methocarbamol | None | 26 | $565 | $22 |
| Ropinirole | None | 15 | $561 | $37 |
| Pramipexole Dihydrochloride | None | 30 | $477 | $16 |
| Clopidogrel | None | 20 | $417 | $21 |
| Ondansetron | None | 15 | $405 | $27 |
| Fluoxetine | None | 13 | $250 | $19 |
| Sumatriptan | None | 24 | $192 | $8 |
| Prednisone | None | 13 | $92 | $7 |
| Diazepam | None | 21 | $21 | $1 |
2022: 37 drugs
| Nuplazid | Parkinson's psychosis | 38 | $168,699 | $4,439 |
| Rytary | Parkinson's | 51 | $67,232 | $1,318 |
| Neupro | None | 32 | $50,887 | $1,590 |
| Carbidopa-Levodopa Er | None | 163 | $26,923 | $165 |
| Rivastigmine | None | 62 | $24,365 | $393 |
| Carbidopa-Levodopa | None | 234 | $18,918 | $81 |
| Myrbetriq | None | 22 | $15,168 | $689 |
| Rasagiline Mesylate | None | 33 | $12,007 | $364 |
| Memantine | None | 120 | $8,934 | $74 |
| Propranolol Hcl Er | None | 62 | $8,442 | $136 |
| Midodrine | None | 30 | $7,053 | $235 |
| Gabapentin | None | 156 | $6,455 | $41 |
| Quetiapine | None | 70 | $4,310 | $62 |
| Donepezil | None | 263 | $4,230 | $16 |
| Glycopyrrolate | None | 12 | $3,924 | $327 |
| Rivastigmine | None | 20 | $3,335 | $167 |
| Galantamine Er | None | 15 | $3,006 | $200 |
| Duloxetine | None | 39 | $2,606 | $67 |
| Mirtazapine | None | 21 | $2,163 | $103 |
| Zonisamide | None | 31 | $2,015 | $65 |
| Pregabalin | None | 26 | $1,749 | $67 |
| Pyridostigmine | None | 18 | $1,717 | $95 |
| Galantamine Hbr | None | 13 | $1,394 | $107 |
| Baclofen | None | 13 | $1,009 | $78 |
| Amantadine | None | 13 | $972 | $75 |
| Primidone | None | 16 | $967 | $60 |
| Propranolol | None | 17 | $879 | $52 |
| Escitalopram | None | 47 | $844 | $18 |
| Nortriptyline | None | 20 | $639 | $32 |
| Cyclobenzaprine | None | 25 | $578 | $23 |
| Pramipexole Dihydrochloride | None | 23 | $471 | $20 |
| Trazodone | None | 42 | $463 | $11 |
| Bupropion Xl | None | 11 | $337 | $31 |
| Clonazepam | None | 28 | $299 | $11 |
| Methocarbamol | None | 12 | $286 | $24 |
| Atorvastatin | None | 13 | $214 | $16 |
| Diazepam | None | 20 | $22 | $1 |
2021: 28 drugs
| Nuplazid | Parkinson's psychosis | 21 | $75,549 | $3,598 |
| Nuedexta | None | 23 | $32,252 | $1,402 |
| Rytary | Parkinson's | 31 | $28,197 | $910 |
| Neupro | None | 23 | $22,956 | $998 |
| Carbidopa-Levodopa | None | 215 | $18,035 | $84 |
| Carbidopa-Levodopa Er | None | 82 | $15,975 | $195 |
| Carbidopa | None | 14 | $15,740 | $1,124 |
| Rivastigmine | None | 41 | $12,914 | $315 |
| Rasagiline Mesylate | None | 29 | $9,652 | $333 |
| Memantine | None | 65 | $4,871 | $75 |
| Quetiapine | None | 35 | $4,796 | $137 |
| Midodrine | None | 30 | $4,046 | $135 |
| Rivastigmine | None | 24 | $3,959 | $165 |
| Propranolol Hcl Er | None | 38 | $3,793 | $100 |
| Zonisamide | None | 52 | $2,357 | $45 |
| Pyridostigmine | None | 20 | $1,827 | $91 |
| Gabapentin | None | 64 | $1,732 | $27 |
| Donepezil | None | 120 | $1,724 | $14 |
| Galantamine Hbr | None | 12 | $989 | $82 |
| Duloxetine | None | 28 | $981 | $35 |
| Propranolol | None | 15 | $834 | $56 |
| Pramipexole Dihydrochloride | None | 16 | $523 | $33 |
| Escitalopram | None | 18 | $337 | $19 |
| Clonazepam | None | 32 | $333 | $10 |
| Sertraline | None | 16 | $308 | $19 |
| Trazodone | None | 24 | $210 | $9 |
| Citalopram Hbr | None | 17 | $143 | $8 |
| Diazepam | None | 15 | $13 | $1 |
2020: 7 drugs
| Rytary | Parkinson's | 24 | $39,280 | $1,637 |
| Carbidopa-Levodopa | None | 63 | $5,700 | $90 |
| Carbidopa-Levodopa Er | None | 48 | $4,250 | $89 |
| Amantadine | None | 12 | $1,719 | $143 |
| Memantine | None | 12 | $730 | $61 |
| Gabapentin | None | 12 | $567 | $47 |
| Donepezil | None | 31 | $545 | $18 |
2019: 17 drugs
| Rytary | Parkinson's | 30 | $70,252 | $2,342 |
| Carbidopa | None | 11 | $23,451 | $2,132 |
| Carbidopa-Levodopa | None | 128 | $11,072 | $87 |
| Carbidopa-Levodopa Er | None | 72 | $9,791 | $136 |
| Entacapone | None | 24 | $8,513 | $355 |
| Rasagiline Mesylate | None | 13 | $6,953 | $535 |
| Amantadine | None | 31 | $3,291 | $106 |
| Midodrine | None | 16 | $2,398 | $150 |
| Pramipexole Dihydrochloride | None | 14 | $1,392 | $99 |
| Propranolol Hcl Er | None | 20 | $1,300 | $65 |
| Trospium Chloride | None | 16 | $1,255 | $78 |
| Donepezil | None | 54 | $1,203 | $22 |
| Gabapentin | None | 25 | $766 | $31 |
| Baclofen | None | 11 | $492 | $45 |
| Quetiapine | None | 14 | $362 | $26 |
| Sertraline | None | 16 | $169 | $11 |
| Clonazepam | None | 24 | $124 | $5 |
2018: 4 drugs
| Entacapone | 11 | $5,334 | $485 |
| Carbidopa-Levodopa | 48 | $3,644 | $76 |
| Carbidopa-Levodopa Er | 19 | $1,423 | $75 |
| Donepezil | 15 | $279 | $19 |
Money from drug and device companies
$4,511 in 2025
| 2025 | 36 | 164 | None | $4,511 |
| 2024 | 29 | 126 | None | $3,563 |
| 2023 | 29 | 155 | None | $4,288 |
| 2022 | 24 | 106 | $1,320 | $3,808 |
| 2021 | 25 | 97 | $1,695 | $3,692 |
| 2020 | 10 | 18 | None | $759 |
| 2019 | 4 | 37 | None | $7,467 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| SK Life Science | None | $421 | 22 payments
|
| Teva Pharmaceuticals USA | Austedo Xr | $376 | 13 payments
|
| Noctrix Health | Nidra | $349 | 1 payment
|
| Eisai | Leqembi | $301 | 8 payments
|
| Pfizer | Nurtec Odt | $261 | 11 payments
|
| Abbvie | Botox | $238 | 14 payments
|
See all 164 published payments
| SK Life Science | Meals · 2025-12-23 | None | $32 |
| Abbvie | Meals · 2025-12-18 | Botox | $13 |
| Ipsen Biopharmaceuticals | Meals · 2025-12-16 | Dysport | $27 |
| Teva Pharmaceuticals USA | Meals · 2025-12-15 | Austedo Xr | $35 |
| Teva Pharmaceuticals USA | Meals · 2025-12-15 | Austedo Xr | $35 |
| Vanda Pharmaceuticals | Meals · 2025-12-12 | Ponvory | $32 |
| Jazz Pharmaceuticals | Meals · 2025-12-12 | Epidiolex | $19 |
| Argenx US | Meals · 2025-12-10 | Vyvgart Hytrulo | $33 |
| ACADIA Pharmaceuticals | Meals · 2025-12-10 | Nuplazid | $24 |
| Amgen | Meals · 2025-12-08 | None | $20 |
| Merz Pharmaceuticals | Meals · 2025-12-05 | Inbrija | $34 |
| Octapharma USA | Meals · 2025-12-04 | Panzyga | $27 |
| Lundbeck | Meals · 2025-12-03 | Vyepti | $23 |
| Pfizer | Meals · 2025-12-02 | Nurtec Odt | $21 |
| SK Life Science | Meals · 2025-11-25 | None | $12 |
| Janssen Biotech | Meals · 2025-11-24 | None | $34 |
| Axsome Therapeutics | Meals · 2025-11-22 | Symbravo | $24 |
| Amneal Pharmaceuticals | Meals · 2025-11-20 | Crexont | $22 |
| Pfizer | Meals · 2025-11-18 | Nurtec Odt | $24 |
| Eisai | Meals · 2025-11-17 | Leqembi | $19 |
| Abbvie | Meals · 2025-11-12 | Ubrelvy | $4 |
| Teva Pharmaceuticals USA | Meals · 2025-11-12 | Austedo Xr | $3 |
| Teva Pharmaceuticals USA | Meals · 2025-11-12 | Austedo Xr | $32 |
| Alexion Pharmaceuticals | Meals · 2025-11-11 | Ultomiris | $31 |
| SK Life Science | Meals · 2025-11-08 | None | $35 |
| Vanda Pharmaceuticals | Meals · 2025-11-07 | Ponvory | $37 |
| CSL Behring | Meals · 2025-11-04 | Hizentra | $23 |
| Argenx US | Meals · 2025-11-04 | Vyvgart Hytrulo | $30 |
| Teva Pharmaceuticals USA | Meals · 2025-10-31 | Austedo Xr | $32 |
| Lundbeck | Meals · 2025-10-31 | Vyepti | $0 |
| Lundbeck | Meals · 2025-10-31 | Vyepti | $29 |
| Ucb | Meals · 2025-10-28 | Nayzilam | $21 |
| Pfizer | Meals · 2025-10-28 | Nurtec Odt | $26 |
| TG Therapeutics | Meals · 2025-10-25 | Briumvi | $28 |
| Merz Pharmaceuticals | Meals · 2025-10-23 | Xeomin | $4 |
| Merz Pharmaceuticals | Meals · 2025-10-23 | Xeomin | $28 |
| Neurocrine BioSciences | Meals · 2025-10-21 | Ingrezza | $33 |
| Otsuka America Pharmaceutical | Meals · 2025-10-20 | Rexulti | $20 |
| Axsome Therapeutics | Meals · 2025-10-17 | Symbravo | $28 |
| Eisai | Meals · 2025-10-16 | Leqembi | $32 |
| TG Therapeutics | Meals · 2025-10-08 | Briumvi | $34 |
| Grifols USA | Meals · 2025-10-03 | Gamunex-C | $31 |
| SK Life Science | Meals · 2025-10-03 | None | $34 |
| Teva Pharmaceuticals USA | Meals · 2025-09-30 | Austedo Xr | $25 |
| Pfizer | Meals · 2025-09-24 | Nurtec Odt | $29 |
| Alexion Pharmaceuticals | Meals · 2025-09-23 | Ultomiris | $32 |
| Lundbeck | Meals · 2025-09-23 | Vyepti | $24 |
| Janssen Biotech | Meals · 2025-09-18 | None | $33 |
| Abbvie | Meals · 2025-09-17 | Ubrelvy | $25 |
| ACADIA Pharmaceuticals | Meals · 2025-09-16 | Nuplazid | $21 |
| Argenx US | Meals · 2025-09-08 | Vyvgart Hytrulo | $23 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-09-05 | Wainua | $16 |
| SK Life Science | Meals · 2025-09-04 | None | $1 |
| SK Life Science | Meals · 2025-09-04 | None | $8 |
| Abbvie | Meals · 2025-09-03 | Botox | $14 |
| Neurocrine BioSciences | Meals · 2025-09-03 | Ingrezza | $31 |
| Abbvie | Meals · 2025-08-29 | Ubrelvy | $28 |
| Merz Pharmaceuticals | Meals · 2025-08-27 | Xeomin | $19 |
| SK Life Science | Meals · 2025-08-23 | None | $34 |
| Lundbeck | Meals · 2025-08-21 | Vyepti | $20 |
| Lundbeck | Meals · 2025-08-21 | Vyepti | $0 |
| Jazz Pharmaceuticals | Meals · 2025-08-20 | Epidiolex | $27 |
| Alexion Pharmaceuticals | Meals · 2025-08-19 | Ultomiris | $33 |
| Pfizer | Meals · 2025-08-19 | Nurtec Odt | $17 |
| Boston Scientific | Meals · 2025-08-15 | Wavewriter Alpha Prime 16 | $52 |
| Argenx US | Meals · 2025-08-14 | Vyvgart Hytrulo | $26 |
| ACADIA Pharmaceuticals | Meals · 2025-08-12 | Nuplazid | $24 |
| SK Life Science | Meals · 2025-08-12 | None | $20 |
| Axsome Therapeutics | Meals · 2025-08-08 | Symbravo | $23 |
| Eisai | Meals · 2025-08-06 | Leqembi | $28 |
| Teva Pharmaceuticals USA | Meals · 2025-07-31 | Austedo Xr | $35 |
| Lilly USA | Meals · 2025-07-29 | Kisunla | $27 |
| SK Life Science | Meals · 2025-07-28 | None | $0 |
| SK Life Science | Meals · 2025-07-28 | None | $10 |
| Neurocrine BioSciences | Meals · 2025-07-17 | Ingrezza | $29 |
| Neurocrine BioSciences | Meals · 2025-07-17 | Ingrezza | $8 |
| Pfizer | Meals · 2025-07-16 | Nurtec Odt | $21 |
| SK Life Science | Meals · 2025-07-14 | None | $34 |
| Mallinckrodt Hospital Products | Meals · 2025-07-11 | Acthar | $19 |
| CSL Behring | Meals · 2025-07-11 | Hizentra | $28 |
| SK Life Science | Meals · 2025-07-10 | None | $10 |
| Lundbeck | Meals · 2025-07-08 | Vyepti | $15 |
| Abbvie | Meals · 2025-07-02 | Botox | $21 |
| Biogen | Meals · 2025-07-02 | Skyclarys | $23 |
| Abbvie | Meals · 2025-06-27 | Qulipta | $8 |
| Lundbeck | Meals · 2025-06-27 | Vyepti | $8 |
| Merz Pharmaceuticals | Meals · 2025-06-26 | Xeomin | $30 |
| Ipsen Biopharmaceuticals | Meals · 2025-06-25 | Dysport | $23 |
| Pfizer | Meals · 2025-06-23 | Nurtec Odt | $27 |
| Teva Pharmaceuticals USA | Meals · 2025-06-18 | Austedo Xr | $39 |
| Alexion Pharmaceuticals | Meals · 2025-06-17 | Ultomiris | $30 |
| BridgeBio Pharma | Meals · 2025-06-13 | Attruby | $32 |
| Neurocrine BioSciences | Meals · 2025-06-12 | Ingrezza | $34 |
| Otsuka America Pharmaceutical | Meals · 2025-06-11 | Rexulti | $26 |
| SK Life Science | Meals · 2025-06-11 | None | $32 |
| Amneal Pharmaceuticals | Meals · 2025-06-06 | Rytary | $29 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-06-05 | Wainua | $18 |
| Eisai | Meals · 2025-06-02 | Leqembi | $20 |
| Pfizer | Meals · 2025-05-28 | Nurtec Odt | $23 |
| Janssen Biotech | Meals · 2025-05-27 | None | $40 |
| MDD US Operations | Meals · 2025-05-22 | None | $143 |
| CSL Behring | Meals · 2025-05-16 | Hizentra | $26 |
| Lilly USA | Meals · 2025-05-15 | Kisunla | $26 |
| Abbvie | Meals · 2025-05-14 | Qulipta | $25 |
| Teva Pharmaceuticals USA | Meals · 2025-05-09 | Austedo Xr | $21 |
| Alexion Pharmaceuticals | Meals · 2025-05-06 | Ultomiris | $31 |
| SK Life Science | Meals · 2025-05-02 | None | $31 |
| Teva Pharmaceuticals USA | Meals · 2025-05-01 | Austedo Xr | $29 |
| Eisai | Meals · 2025-04-30 | Leqembi | $22 |
| Lundbeck | Meals · 2025-04-28 | Vyepti | $18 |
| Merz Pharmaceuticals | Meals · 2025-04-25 | Xeomin | $37 |
| SK Life Science | Meals · 2025-04-25 | None | $1 |
| SK Life Science | Meals · 2025-04-25 | None | $7 |
| Pfizer | Meals · 2025-04-24 | Nurtec Odt | $25 |
| Boston Scientific | Meals · 2025-04-21 | General - Dbs | $134 |
| Teva Pharmaceuticals USA | Meals · 2025-04-16 | Austedo Xr | $35 |
| Otsuka America Pharmaceutical | Meals · 2025-04-15 | Rexulti | $19 |
| Amneal Pharmaceuticals | Meals · 2025-04-11 | Rytary | $26 |
| Lundbeck | Meals · 2025-04-09 | Vyepti | $8 |
| SK Life Science | Meals · 2025-04-08 | None | $26 |
| Neurelis | Meals · 2025-04-07 | Valtoco | $24 |
| Abbvie | Meals · 2025-04-04 | Qulipta | $3 |
| Abbvie | Meals · 2025-04-04 | Botox | $19 |
| Biogen | Meals · 2025-04-04 | Vumerity | $27 |
| Lilly USA | Meals · 2025-04-03 | Kisunla | $32 |
| SK Life Science | Meals · 2025-04-03 | None | $8 |
| Octapharma USA | Meals · 2025-04-01 | Panzyga | $35 |
| Pfizer | Meals · 2025-03-31 | Nurtec Odt | $19 |
| Ucb | Meals · 2025-03-28 | Briviact | $18 |
| Noctrix Health | Meals · 2025-03-27 | Nidra | $349 |
| Eisai | Meals · 2025-03-26 | Leqembi | $22 |
| Argenx US | Meals · 2025-03-25 | Vyvgart Hytrulo | $24 |
| Alexion Pharmaceuticals | Meals · 2025-03-24 | Ultomiris | $29 |
| MDD US Operations | Meals · 2025-03-21 | None | $34 |
| Abbvie | Meals · 2025-03-12 | Ubrelvy | $21 |
| Eisai | Meals · 2025-03-12 | Leqembi | $125 |
| Abbvie | Meals · 2025-03-06 | Qulipta | $8 |
| Amneal Pharmaceuticals | Meals · 2025-03-06 | Rytary | $23 |
| SK Life Science | Meals · 2025-03-06 | None | $9 |
| Abbvie | Meals · 2025-03-05 | Botox | $20 |
| Otsuka America Pharmaceutical | Meals · 2025-03-04 | Rexulti | $20 |
| Grifols USA | Meals · 2025-03-03 | Gamunex-C | $27 |
| MDD US Operations | Meals · 2025-02-26 | Gocovri | $21 |
| Ucb | Meals · 2025-02-21 | Rystiggo | $25 |
| SK Life Science | Meals · 2025-02-21 | None | $34 |
| Eisai | Meals · 2025-02-19 | Leqembi | $32 |
| Abbvie | Meals · 2025-02-18 | Botox | $28 |
| Pfizer | Meals · 2025-02-17 | Nurtec Odt | $28 |
| Lundbeck | Meals · 2025-02-12 | Vyepti | $24 |
| Impel Pharmaceuticals | Meals · 2025-02-11 | Trudhesa | $18 |
| Teva Pharmaceuticals USA | Meals · 2025-02-06 | Austedo Xr | $31 |
| ANI Pharmaceuticals | Meals · 2025-02-05 | Purified Cortrophin Gel | $29 |
| MDD US Operations | Meals · 2025-02-04 | None | $14 |
| Neurocrine BioSciences | Meals · 2025-02-04 | Ingrezza | $34 |
| SK Life Science | Meals · 2025-01-28 | None | $19 |
| Biogen | Meals · 2025-01-16 | Skyclarys | $30 |
| Lundbeck | Meals · 2025-01-16 | Vyepti | $12 |
| Lundbeck | Meals · 2025-01-16 | Vyepti | $1 |
| Lundbeck | Meals · 2025-01-16 | Vyepti | $2 |
| EMD Serono | Meals · 2025-01-14 | None | $29 |
| Biogen | Meals · 2025-01-09 | Skyclarys | $29 |
| Teva Pharmaceuticals USA | Meals · 2025-01-09 | Austedo Xr | $24 |
| Ucb | Meals · 2025-01-06 | Briviact | $20 |
| SK Life Science | Meals · 2025-01-03 | None | $23 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $3,563
| MDD US Operations | Gocovri | $443 | 9 payments
|
| Teva Pharmaceuticals USA | Austedo Xr | $371 | 12 payments
|
| Abbvie | Ubrelvy | $332 | 15 payments
|
| SK Life Science | None | $240 | 11 payments
|
| Biogen | Tysabri | $212 | 8 payments
|
| Alexion Pharmaceuticals | Ultomiris | $203 | 8 payments
|
| Neurocrine Biosciences | Ingrezza | $186 | 5 payments
|
| Pfizer | Nurtec Odt | $144 | 6 payments
|
| Boston Scientific | None | $125 | 1 payment
|
| Corium | Azstarys | $119 | 5 payments
|
| Jazz Pharmaceuticals | Epidiolex | $107 | 4 payments
|
| Lilly USA | Amyvid | $100 | 4 payments
|
| Ucb | Briviact | $96 | 4 payments
|
| Acorda Therapeutics | Inbrija | $92 | 4 payments
|
| Kyowa Kirin | Nourianz | $83 | 3 payments
|
| Argenx US | Vyvgart Hytrulo | $81 | 3 payments
|
| Eisai | Leqembi | $77 | 3 payments
|
| Neurelis | Valtoco | $76 | 2 payments
|
| Genentech USA | Ocrevus | $74 | 3 payments
|
| Otsuka America Pharmaceutical | Nuedexta | $70 | 3 payments
|
| Octapharma USA | Panzyga | $60 | 2 payments
|
| Lundbeck | Vyepti | $59 | 2 payments
|
| Sumitomo Pharma America | Aptiom | $53 | 2 payments
|
| Tris Pharma | Dyanavel Xr | $43 | 2 payments
|
| Amneal Pharmaceuticals | Rytary | $26 | 1 payment
|
| Mallinckrodt Hospital Products | Acthar | $26 | 1 payment
|
| Banner Life Sciences | Bafiertam | $25 | 1 payment
|
| Azurity Pharmaceuticals | None | $20 | 1 payment
|
| ANI Pharmaceuticals | Purified Cortrophin Gel | $18 | 1 payment
|
2023: $4,288
| Neurocrine Biosciences | Ingrezza | $590 | 11 payments
|
| AbbVie | Botox | $572 | 22 payments
|
| Teva Pharmaceuticals USA | Austedo Xr | $551 | 17 payments
|
| Impel Pharmaceuticals | Trudhesa | $264 | 20 payments
|
| Acorda Therapeutics | Inbrija | $212 | 10 payments
|
| Jazz Pharmaceuticals | Epidiolex | $203 | 8 payments
|
| Alexion Pharmaceuticals | Ultomiris | $196 | 5 payments
|
| Argenx US | Vyvgart | $168 | 5 payments
|
| Sumitomo Pharma America | Aptiom | $160 | 8 payments
|
| SK Life Science | None | $155 | 7 payments
|
| Medtronic | Percept PC Brainsense | $139 | 1 payment
|
| Si-Bone | None | $129 | 1 payment
|
| Otsuka America Pharmaceutical | Nuedexta | $104 | 4 payments
|
| MDD US Operations | None | $100 | 5 payments
|
| Pfizer | Nurtec Odt | $92 | 4 payments
|
| Ucb | Briviact | $76 | 3 payments
|
| Lilly USA | Emgality | $75 | 3 payments
|
| Biogen | Tysabri | $71 | 3 payments
|
| Amneal Pharmaceuticals | Rytary | $70 | 3 payments
|
| Genentech USA | Ocrevus | $53 | 2 payments
|
| ACADIA Pharmaceuticals | Daybue | $50 | 2 payments
|
| ANI Pharmaceuticals | Purified Cortrophin Gel | $46 | 2 payments
|
| Lundbeck | Vyepti | $45 | 2 payments
|
| Neurelis | Valtoco | $33 | 1 payment
|
| Life Molecular Imaging | Neuraceq | $33 | 1 payment
|
| Averitas Pharma | Qutenza | $30 | 1 payment
|
| Banner Life Sciences | Bafiertam | $27 | 1 payment
|
| Kyowa Kirin | Nourianz | $22 | 1 payment
|
| Celgene | None | $22 | 1 payment
|
2022: $3,808
| Eisai | None | $1,320 | 1 payment
|
| Teva Pharmaceuticals USA | Austedo | $391 | 12 payments
|
| Neurocrine Biosciences | Ongentys | $253 | 9 payments
|
| Sunovion Pharmaceuticals | Kynmobi | $204 | 9 payments
|
| Abbvie | Botox | $197 | 11 payments
|
| Acorda Therapeutics | Inbrija | $171 | 10 payments
|
| Biohaven Pharmaceutical Holding Company | Nurtec Odt | $156 | 17 payments
|
| Medtronic | Percept PC Brainsense | $147 | 2 payments
|
| Boston Scientific | General - Dbs | $137 | 2 payments
|
| SK Life Science | None | $107 | 4 payments
|
| Jazz Pharmaceuticals | Epidiolex | $103 | 4 payments
|
| Avanir Pharmaceuticals | Nuedexta | $85 | 4 payments
|
| GE HealthCare | None | $84 | 2 payments
|
| GRT US Holding | Qutenza | $69 | 2 payments
|
| Ucb | Briviact | $58 | 2 payments
|
| MDD US Operations | None | $58 | 3 payments
|
| Janssen Pharmaceuticals | Ponvory | $56 | 2 payments
|
| Kyowa Kirin | Nourianz | $44 | 2 payments
|
| Exeltis USA | Purified Cortrophin Gel | $44 | 2 payments
|
| Avion Pharmaceuticals | Dhivy | $37 | 2 payments
|
| Alexion Pharmaceuticals | Soliris | $24 | 1 payment
|
| Allergan | Botox | $23 | 1 payment
|
| ACADIA Pharmaceuticals | Nuplazid | $20 | 1 payment
|
| Ultragenyx Pharmaceutical | None | $20 | 1 payment
|
2021: $3,692
| Eisai | None | $1,568 | 1 payment
|
| Teva Pharmaceuticals USA | Ajovy | $443 | 11 payments
|
| Biohaven Pharmaceuticals | Nurtec Odt | $225 | 19 payments
|
| Boston Scientific | General Dbs | $184 | 5 payments
|
| Ucb | Briviact | $151 | 7 payments
|
| SK Life Science | None | $136 | 6 payments
|
| Acorda Therapeutics | Inbrija | $127 | 3 payments
|
| AbbVie | Vraylar | $113 | 7 payments
|
| Neurocrine Biosciences | Ingrezza | $93 | 4 payments
|
| Alexion Pharmaceuticals | Soliris | $81 | 5 payments
|
| Kyowa Kirin | Nourianz | $70 | 4 payments
|
| Greenwich Biosciences | Epidiolex | $65 | 3 payments
|
| Adamas Pharmaceuticals | Gocovri | $59 | 3 payments
|
| Sunovion Pharmaceuticals | Kynmobi | $58 | 5 payments
|
| Allergan | Botox | $52 | 2 payments
|
| Biogen | Aduhelm | $45 | 2 payments
|
| Ge Healthcare | None | $40 | 2 payments
|
| Medtronic | Percept | $33 | 1 payment
|
| Lilly USA | Emgality | $28 | 1 payment
|
| Amgen | Aimovig | $25 | 1 payment
|
| Catalyst Pharmaceuticals | Firdapse | $23 | 1 payment
|
| Arbor Pharmaceuticals | Horizant | $22 | 1 payment
|
| Avanir Pharmaceuticals | Nuedexta | $20 | 1 payment
|
| Merz Pharmaceuticals | Xeomin | $18 | 1 payment
|
| ACADIA Pharmaceuticals | Nuplazid | $12 | 1 payment
|
2020: $759
| Kyowa Kirin | Nourianz | $149 | 2 payments
|
| Boston Scientific | General - Dbs | $146 | 1 payment
|
| Medtronic USA | Activa | $134 | 3 payments
|
| ACADIA Pharmaceuticals | Nuplazid | $82 | 2 payments
|
| SK Life Science | None | $72 | 2 payments
|
| US WorldMeds | Xadago | $69 | 3 payments
|
| Neurocrine Biosciences | Ingrezza | $50 | 2 payments
|
| GE Healthcare | None | $23 | 1 payment
|
| Adamas Pharmaceuticals | Gocovri | $22 | 1 payment
|
| Teva Pharmaceuticals USA | Ajovy | $13 | 1 payment
|
2019: $7,467
| Medtronic USA | Activa | $6,842 | 30 payments
|
| Boston Scientific | Spectra Wavewriter | $335 | 4 payments
|
| Teva Pharmaceuticals USA | Austedo | $266 | 2 payments
|
| AbbVie | Duopa | $24 | 1 payment
|
Checkups this office reported
17 measures · 2023
Medicare asked this office to report how often certain checkups happened in 2023. This is not a grade for the doctor. A specialist’s patients may not need every screening.
- Medicare’s overall office score
- 87.3 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
| Appropriate Treatment for Upper Respiratory Infection (URI)As Medicare defines this measure | 100% | 30 |
| Asked about smokingPatients asked about tobacco, with help to quit if they smoke | 71%That's more than half. | 741 |
| Blood pressure under controlPeople with high blood pressure whose reading was in a healthy range | 57%That's more than half. | 420 |
| Bone-density scans that were not neededYounger women who got a bone scan without a medical reason | 0%That's few of the people this applied to. Better on this measure. | 81 |
| Breast cancer screeningEligible women who got a mammogram | 37%That's less than half. | 321 |
| Cervical cancer screeningEligible women who got a Pap or HPV test | 15%That's few of the people this applied to. | 296 |
| Checked for fall riskOlder patients screened for fall risk | 63%That's more than half. | 915 |
| Colon cancer screeningEligible adults who got a colon cancer test | 24%That's few of the people this applied to. | 684 |
See the other 9 measures
| Depression screeningPatients screened for depression, with a follow-up plan if needed | 11%That's few of the people this applied to. | 1,222 |
| Diabetes eye examPeople with diabetes who got a retinal eye exam | 3%That's few of the people this applied to. | 118 |
| Diabetes poorly controlledPeople with diabetes whose blood sugar stayed very high | 61%That's more than half. Worse on this measure. | 118 |
| HIV screeningEligible patients who were screened for HIV | 47%That's less than half. | 652 |
| Medications listed in the chartVisits where the current medication list was documented | 98%That's most of the people this applied to. | 2,793 |
| Patients can see their records onlinePatients who were given electronic access to their health information | 100%That's most of the people this applied to. | 888 |
| Prescriptions sent electronicallyPrescriptions sent to the pharmacy by computer instead of paper | 100%That's most of the people this applied to. | 956 |
| Statin prescribed when it protects the heartPeople at cardiovascular risk who were prescribed a statin | 77%That's most of the people this applied to. | 676 |
| Weight checked, with a follow-up planPatients whose BMI was recorded and followed up if needed | 43%That's less than half. | 1,488 |
What the office says it does
Boxes the office ticked on its Medicare worksheet for 2023. Nobody checks these.
- Agreed to federal review of their records system
- Checks the state prescription-drug database before prescribing
- Did a security review of patient data
- Exchanges records both ways with other health systems
- Improved the patient portal
- Lets patients read their visit notes
- Reports cases to public health electronically
- Shows lab and imaging costs when ordering tests
- Uses standard treatment protocols
- Exempt from immunization registry reporting
Professional record
- NPI
- 1164840963
- Licence
- CA A153605California A153605: Current · expires 2027-03-31
- Trained
- Medical College of Georgia School of Medicine, 2014
- Group
- Bass Medical Group
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Neurology (2084N0400X)
- Mailing address
- 18431 Technology Dr, Morgan Hill, CA, 95037
- NPI first listed
- 2014-03-31
- NPI last updated
- 2025-02-27
- NPI record certified
- 2025-02-27
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 16130 Juan Hernandez Dr Ste 110, Morgan Hill, CA, 95037 · 1635 Divisadero St Ste 520, San Francisco, CA, 94115 · 4150 Clement St, San Francisco, CA, 94121